

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-15 (Canceled)

Claim 16 (Currently Amended): A formulation consisting essentially of

~~at least one EPA selected from the group consisting of: gamma linolenic acid; dihomogammalinolenic acid; arachidonic acid; adrenic acid; docosapentaenoic acid; stearidonic acid; eicosatetraenoic acid (n-3); eicosapentaenoic acid (EPA) or derivative; docosapentaenoic acid (n-3) and docosahexaenoic acid;~~

~~at least one homocysteine lowering agent selected from the group consisting of: vitamin B12; folic acid, at a maximum daily dose of 5 mg; and vitamin B6, at a maximum daily dose of 20 mg; and,~~

~~optionally, at least one antioxidant.~~

Claim 17 (Previously Amended): The formulation of claim 16, wherein the formulation is a pharmaceutical formulation.

Claim 18 (Original): The formulation of claim 16, wherein the formulation is a nutritional formulation.

Claim 19 (Original): The formulation of claim 16, wherein the formulation is in the form of a hard gelatin capsule or a soft gelatin capsule.

Claims 20 - 21 (Canceled)

Claim 22 (Currently Amended): The formulation of claim 16, wherein ~~the homocysteine lowering agent is 5 mg of vitamin B12~~ the EPA or derivative has a purity of more than 90%.

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

Claim 23 (Currently Amended): The formulation of claim 16, wherein ~~the at least one EPA is a eicosapentaenoic acid (EPA)~~ the EPA or derivative has a purity of more than 95%.

Claim 24 (Currently Amended): The formulation of claim ~~23~~ 16, wherein the ~~eicosapentaenoic acid (EPA)~~ or derivative is the ethyl ester form or the pure tri-EPA triglyceride ~~form.~~

Claim 25 (Currently Amended): The formulation of claim 16, ~~wherein the EPA is arachidonic acid~~ having 500mg of EPA, 1 mg of hydroxocobalamin, 1mg of folic acid and 2mg of pyridoxine.

Claim 26 (Currently Amended): The formulation of claim 16, ~~wherein the EPA is gammalinolenic acid or dihomogammalinolenic acid~~ having 500mg of EPA, 1 mg of hydroxocobalamin, 1mg of folic acid and 5mg of pyridoxine.

Claims 27 – 36 (Cancelled)

Claim 37 (Currently Amended): The formulation of claim 16, wherein folic acid is ~~the only homocysteine lowering agent~~ replaced by methyltetrahydrofolate.

Claim 38 (Original): The formulation of claim 16, wherein the formulation is in a form suitable for oral administration.

Claim 39 (Currently Amended): The formulation of claim 16 having an antioxidant, wherein the antioxidant is selected from the group consisting of: natural, synthetic or semi-synthetic vitamin E; natural, synthetic or semi-synthetic coenzyme Q; natural, synthetic or semi-synthetic alpha-lipoic acid; and natural, synthetic or semi-synthetic vitamin C.

Claims 40-45 (Canceled)

Claim 46 (Currently Amended): ~~The method of claim 44, wherein the A method for treating a subject suffers suffering~~ from one or more of the following conditions selected from the group consisting of:

Appl. No. 09/615,736
Reply to Office Action of October 21, 2003

Attorney Docket: P65773US0

~~— (a) a cardiovascular disorder; a cerebrovascular disorder; atherosclerosis; heart disease; cerebrovascular disease; stroke; peripheral vascular disease; thrombosis;~~

~~— (b) diabetes; pre diabetes (syndrome X); macrovascular complications of diabetes; microvascular complications of diabetes; cardiovascular disease; retinopathy; nephropathy; neuropathy;~~

~~— (c) a psychiatric disorder; schizophrenia; a schizotypal disorder; a and other schizopreni form disorder; bipolar disorder (mania, or manic depression); depression; a panic disorder; an anxiety disorder; a sleep disorder; a social phobia;~~

~~— (d) a neurological disorder; a neurodegenerative disorder; Alzheimer's disease; dementia; Parkinson's disease; multiple sclerosis; and Huntington's disease; chronic pain;~~

~~— (e) a kidney disorder;~~

~~— (f) an inflammatory or an immunological disorder of the gastrointestinal tract, the respiratory system, the skin and mucous membranes, or the joints or other tissues;~~

~~— (g) an eye or hearing disorder; age related macular degeneration; age related deafness; tinnitus;~~

~~— (h) obesity; or~~

~~— (i) cancer which comprises administering to the subject the formulation of claim 16.~~

Claims 47 – 48 (Cancelled)